INTELGENX TECHNOLOGIES CORP (OTCMKTS:IGXT) Reports Increase in Sellers; Strong Momentum for Short Players

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Logo

The stock of INTELGENX TECHNOLOGIES CORP (OTCMKTS:IGXT) registered an increase of 69.84% in short interest. IGXT’s total short interest was 10,700 shares in September as published by FINRA. Its up 69.84% from 6,300 shares, reported previously. With 64,300 shares average volume, it will take short sellers 0 days to cover their IGXT’s short positions.

The stock increased 3.05% or $0.014 during the last trading session, reaching $0.475. About 17,175 shares traded. IntelGenx Technologies Corp. (OTCMKTS:IGXT) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.

IntelGenx Technologies Corp., a drug delivery company, develops novel oral immediate-release and controlled-release products for the pharmaceutical market. The company has market cap of $44.43 million. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. It currently has negative earnings. The companyÂ’s products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2012 for schizophrenia; and INT0043/2015 to treat mild cognitive impairment and AlzheimerÂ’s disease.

More notable recent IntelGenx Technologies Corp. (OTCMKTS:IGXT) news were published by: which released: “IntelGenx and Tilray on go with Q4 launch of cannabis-infused oral film – Seeking Alpha” on January 14, 2019, also with their article: “IntelGenx: A Small Cap With A Big Pipeline In Cannabis, Alzheimer’s, And ED – Seeking Alpha” published on September 26, 2018, published: “CURE Pharmaceutical Readies $12 Million U.S. IPO – Seeking Alpha” on December 06, 2018. More interesting news about IntelGenx Technologies Corp. (OTCMKTS:IGXT) were released by: and their article: “CURE Pharmaceutical IPO: Overvalued At 314x Forward Sales – Seeking Alpha” published on December 11, 2018 as well as‘s news article titled: “IntelGenx teams up with Tilray to develop oral film cannabis products – Seeking Alpha” with publication date: November 07, 2018.

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.